MedTrace Logo

A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects

NCT04818229 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2024-11-04

Study results available
· View outcomes & findings →

Summary

This study will investigate the effects of therapeutic and supratherapeutic oral doses of CBP-307 on the QTc interval in healthy subjects.

Conditions

Interventions

DRUG

CBP-307

CBP-307 capsules oral administration.

DRUG

Placebo-matched CBP-307

Placebo-matched CBP-307 capsules oral administration.

DRUG

Moxifloxacin (Avelox)

Moxifloxacin tablets oral administration。

DRUG

Placebo-matched Moxifloxacin

Placebo-matched Moxifloxacin tablets oral administration.

Sponsors & Collaborators

  • Connect Biopharma Australia Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Australia Connect · Connect Biopharma Australia Pty Ltd

  • Suzhou Connect · Connect Biopharm LLC

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-03-20
Completion
2022-03-30
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04818229 on ClinicalTrials.gov